MilliporeSigma
HomePress ReleasesMilliporeSigma Announces Strategic Agreement with GI Innovation to Facilitate Biomedicine Development in Korea

MilliporeSigma Announces Strategic Agreement with GI Innovation to Facilitate Biomedicine Development in Korea

News Release

  • Alliance to focus on accelerating immuno-oncology drug and allergy therapy development & manufacturing
  • Life Science business sector to provide technologies and services, including CHOZN® platform, cell culture media, and downstream process development

Burlington, MA, November 11, 2021 – MilliporeSigma, the U.S. and Canada business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that the Life Science business sector signed a Memorandum of Understanding (MoU) with local bio-venture company GI Innovation, to further research and development of critical life-saving cancer treatments, as well as drugs for allergy-related conditions.

“Our collaboration with GI Innovation aims to support our novel, fusion protein drug discovery, as well as accelerate access to cancer treatments and allergy medicines to patients worldwide,” said Yong-seog Kim, Head of Process Solutions, Life Science business sector of Merck KGaA, Darmstadt, Germany, in Korea. “Our deep expertise in bioprocessing development enables us to provide our customers with solutions needed to address challenges throughout the biopharma value chain.”

Through the mutual agreement, the Life Science business sector will support GI Innovation with technologies and services including CHOZN® platform, cell culture media, and overall process consulting and technical support.

“With this agreement, we have the potential to reduce time and cost of manufacturing by leveraging the technical capabilities of GI Innovation and the bioprocessing expertise of the Life Science business of Merck KGaA, Darmstadt, Germany,” said Joonho Hong, CEO of GI Innovation. “As this is the first collaboration model with the Life Science business, I look forward to great outcomes from the synergy we create from both companies,” he added.

The MoU outlines the Life Science business sector’s long-term plan in supporting pharmaceutical and biotech companies to develop and manufacture drugs safely, effectively, and cost efficiently.

About the Life Science business of Merck KGaA, Darmstadt, Germany 

The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has more than 23,000 employees and 59 manufacturing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services. Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and electronics.

Around 58,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene-editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2020, Merck KGaA, Darmstadt, Germany generated sales of € 17.5 billion in 66 countries.

The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Electronics. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck KGaA, Darmstadt, Germany, visit www.emdgroup.com.

All Merck KGaA, Darmstadt, Germany news releases are distributed by email at the same time they become available on the EMD Group website. In case you are a resident of the U.S. or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service. 

Follow MilliporeSigma on Twitter @MilliporeSigma, on Facebook @MilliporeSigma and on LinkedIn.